Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )

38.62 -0.06 (-0.16%)
Streaming Delayed Price Updated: 12:09 PM EST, Jan 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 127,427
Open 38.58
Bid (Size) 38.57 (1)
Ask (Size) 38.63 (3)
Prev. Close 38.68
Today's Range 38.32 - 39.30
52wk Range 6.510 - 41.93
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
 
Via Benzinga
Amylyx: An "Ice Bucket" Buy
The drug was green-lighted by the Food & Drug Administration last month, after clinical trials partially funded by Ice Bucket Challenge grants showed that Relyvrio takers had a median survival period... 
Via Talk Markets

Performance

YTD
+7.34%
+7.34%
1 Month
+7.34%
+7.34%
3 Month
+8.27%
+8.27%
6 Month
+49.63%
+49.63%
1 Year
+66.61%
+66.61%

More News

Read More
100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make Miracles
Via Investor's Business Daily
Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
Via Investor's Business Daily
Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Where Amylyx Pharma Stands With Analysts
Via Benzinga
Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
Via Investor's Business Daily
Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Launch of Public Offering
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Vyant Bio Inc. (NASDAQ: VYNT): Leading a New Biotech Move to Combat Diseases Affecting the Nervous System
Via Benzinga
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Via Benzinga
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
Via Benzinga
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Bounce In Futures Fizzles As Dollar Surge Returns
Via Talk Markets
Why Is IONQ Stock Up 8% Today?
Via InvestorPlace
AMLX Stock Alert: Amylyx Pharma Gains on Huge FDA Win
Via InvestorPlace
Why Amylyx Pharmaceuticals Is Trading Higher By Over 8%; Here Are 22 Stocks Moving Premarket
Via Benzinga
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
IPO Scorcher Amylyx Wins FDA Approval In ALS Treatment, Ending A Long Battle
Via Investor's Business Daily
Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test
Via Investor's Business Daily
Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Publication of Preclinical Data Showing Potential Synergistic Effect of AMX0035 Compared to Individual Compounds
From Amylyx Pharmaceuticals
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.